Krystal Biotech (NASDAQ:KRYS) Shares Gap Up After Analyst Upgrade

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating)’s stock price gapped up prior to trading on Monday after Guggenheim raised their price target on the stock from $101.00 to $130.00. The stock had previously closed at $96.06, but opened at $101.34. Krystal Biotech shares last traded at $106.48, with a volume of 220,685 shares traded.

KRYS has been the subject of several other research reports. Stifel Nicolaus initiated coverage on shares of Krystal Biotech in a research note on Monday, April 17th. They set a “buy” rating and a $102.00 target price for the company. Bank of America boosted their target price on shares of Krystal Biotech from $105.00 to $118.00 in a research note on Sunday. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research note on Wednesday, March 22nd. Chardan Capital boosted their target price on shares of Krystal Biotech from $133.00 to $148.00 in a research note on Monday. Finally, HC Wainwright boosted their target price on shares of Krystal Biotech from $119.00 to $139.00 in a research note on Monday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average price target of $126.83.

Insider Buying and Selling

In other Krystal Biotech news, Director Dino A. Rossi sold 40,000 shares of the company’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total value of $3,330,000.00. Following the completion of the sale, the director now directly owns 83,691 shares of the company’s stock, valued at approximately $6,967,275.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Krystal Biotech news, Director Dino A. Rossi sold 40,000 shares of the company’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total value of $3,330,000.00. Following the completion of the sale, the director now directly owns 83,691 shares of the company’s stock, valued at approximately $6,967,275.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel Janney sold 7,900 shares of the company’s stock in a transaction dated Wednesday, April 19th. The shares were sold at an average price of $90.32, for a total transaction of $713,528.00. Following the sale, the director now directly owns 224,462 shares of the company’s stock, valued at $20,273,407.84. The disclosure for this sale can be found here. Insiders sold 90,000 shares of company stock valued at $7,786,432 over the last 90 days. 17.00% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

A number of hedge funds have recently bought and sold shares of KRYS. Bank of New York Mellon Corp lifted its stake in Krystal Biotech by 4.1% during the first quarter. Bank of New York Mellon Corp now owns 86,895 shares of the company’s stock valued at $5,782,000 after buying an additional 3,444 shares in the last quarter. MetLife Investment Management LLC boosted its position in Krystal Biotech by 54.4% during the first quarter. MetLife Investment Management LLC now owns 10,266 shares of the company’s stock worth $683,000 after purchasing an additional 3,618 shares during the period. Rhumbline Advisers boosted its position in Krystal Biotech by 10.0% during the first quarter. Rhumbline Advisers now owns 23,839 shares of the company’s stock worth $1,586,000 after purchasing an additional 2,172 shares during the period. BlackRock Inc. boosted its position in shares of Krystal Biotech by 4.9% in the first quarter. BlackRock Inc. now owns 1,683,511 shares of the company’s stock valued at $112,020,000 after acquiring an additional 78,015 shares during the period. Finally, Great West Life Assurance Co. Can boosted its position in shares of Krystal Biotech by 51.9% in the first quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock valued at $72,000 after acquiring an additional 346 shares during the period. 80.80% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Up 22.4 %

The company has a market capitalization of $3.03 billion, a P/E ratio of -22.26 and a beta of 0.85. The firm has a 50-day moving average price of $84.08 and a two-hundred day moving average price of $80.18.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last posted its quarterly earnings data on Monday, February 27th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.01. On average, analysts predict that Krystal Biotech, Inc. will post -5.85 EPS for the current fiscal year.

About Krystal Biotech

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.